[Endocrinology: what's new in 2023].

Fertility preservation in men with Klinefelter's syndrome was addressed by important studies published in 2023.

• The paper identifies this as a significant topic in reproductive endocrinology for 2023.
• Klinefelter's syndrome is associated with male infertility, making fertility preservation a key clinical concern.
• The studies were selected based on their impact on clinical practice.

The cardiovascular safety of testosterone replacement therapy was examined in important 2023 studies.

• This topic was highlighted as having an impact on clinical practice in reproductive endocrinology.
• The study was selected among key 2023 publications for its clinical relevance.
• Cardiovascular safety represents a major concern in the benefit-risk assessment of testosterone replacement therapy.

Fezolinetant was identified as a novel therapy for vasomotor symptoms of menopause.

• Fezolinetant was described as a 'nouvelle thérapie' (novel therapy) for menopausal vasomotor symptoms.
• This represents a new therapeutic option in reproductive endocrinology.
• The therapy was highlighted among the most clinically impactful studies of 2023.

Updated European recommendations concerning adrenal incidentalomas are expected to considerably modify current clinical practice.

• The paper states these updated recommendations 'vont considérablement modifier la pratique clinique' (will considerably modify clinical practice).
• The recommendations were published or updated in 2023.
• Adrenal incidentalomas represent a common clinical challenge in endocrinology.

The prevalence of pituitary adenomas was confirmed to affect approximately 1 per 1000 individuals.

• This prevalence estimate is described as based on 'un travail épidémiologique solide' (solid epidemiological work).
• The finding was published in 2023 and selected for its impact on clinical practice.
• The prevalence figure of approximately 1 per 1000 individuals represents a confirmed epidemiological benchmark.

A large British study allowed refinement of the benefit-risk profile of the three available options for hyperthyroidism treatment.

• The study was described as a 'large étude britannique' (large British study).
• Three treatment options for hyperthyroidism are available and were compared in terms of benefit-risk profile.
• The study was identified as having a significant impact on clinical practice in endocrinology for 2023.